| scholarly article | Q13442814 |
| P50 | author | Toni Ibrahim | Q46672675 |
| Laura Mercatali | Q46672692 | ||
| Flavia Foca | Q52958617 | ||
| Alberto Bongiovanni | Q57009086 | ||
| Alessandro De Vita | Q57009102 | ||
| Stefano Severi | Q57132895 | ||
| Chiara Liverani | Q63761435 | ||
| Giovanni Martinelli | Q90955283 | ||
| Chiara Spadazzi | Q90972234 | ||
| P2093 | author name string | Federica Recine | |
| Federica Pieri | |||
| Giacomo Miserocchi | |||
| Nada Riva | |||
| Silvia Nicolini | |||
| P2860 | cites work | Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. | Q43611737 |
| Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study | Q43905778 | ||
| Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis | Q47593948 | ||
| Recent updates on grading and classification of neuroendocrine tumors. | Q47667910 | ||
| Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role | Q47770029 | ||
| Cyto-histology in NET: what is necessary today and what is the future? | Q47965331 | ||
| Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. | Q51571439 | ||
| Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. | Q53425366 | ||
| Grading of pancreatic neuroendocrine neoplasms using pharmacokinetic parameters derived from dynamic contrast-enhanced MRI. | Q55255348 | ||
| ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin | Q57289794 | ||
| Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation | Q57758753 | ||
| The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond | Q90891655 | ||
| Gastroenteropancreatic high-grade neuroendocrine carcinoma | Q26998392 | ||
| DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors | Q28303693 | ||
| The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. | Q34464857 | ||
| Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways | Q35216414 | ||
| Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors | Q35681234 | ||
| First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma | Q36352317 | ||
| Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors | Q36541359 | ||
| Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). | Q36741130 | ||
| Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas | Q37182620 | ||
| Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival | Q37326199 | ||
| Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers | Q37578830 | ||
| The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature | Q38241845 | ||
| Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. | Q38610333 | ||
| A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas | Q38853033 | ||
| Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma | Q39044979 | ||
| The status of neuroendocrine tumor imaging: from darkness to light? | Q39127977 | ||
| Are G3 ENETS neuroendocrine neoplasms heterogeneous? | Q39386499 | ||
| Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? | Q40182879 | ||
| Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. | Q40309350 | ||
| The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories | Q40499461 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 6878409 | |
| P577 | publication date | 2018-12-02 | |
| P1433 | published in | Disease Markers | Q15756044 |
| P1476 | title | Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers | |
| P478 | volume | 2018 |
Search more.